Please go to the PowerPak homepage
and select a course.
Precision Therapy in NSCLC: Pharmacist Perspectives on Testing Strategies and Biomarker-driven Treatment Approaches
This educational activity is presented by Creative Educational Concepts,
Inc., and is supported by an independent educational grant from AstraZeneca.
This CPE activity is based on the slides and lectures presented by faculty during a live, virtual symposium for the Hematology/Oncology Pharmacy Association’s (HOPA) 16th Annual Conference on Friday, March 13, 2020.
Josiah D. Land, PharmD, BCOP
Clinical Pharmacy Specialist
Thoracic Medical Oncology Team
Memorial Sloan Kettering Cancer Center
New York, New York
Zofia Piotrowska, MD, MHS
Instructor of Medicine
Harvard Medical School
Assistant in Medicine
Massachusetts General Hospital
The discovery of genetic and immunologic biomarkers in non–small-cell lung cancer (NSCLC) and the increasing development of biomarker-specific targeted therapies and immunotherapies have transformed the treatment landscape of advanced NSCLC. However, these rapid changes in the field also present the challenge of translating recent trial data and the latest guideline recommendations into clinical practice.
This immersive case-based activity, will challenge participants to apply the latest data to NSCLC treatment decisions. Participants are provided with evidence-based information on the latest developments in NSCLC, including updates on biomarker testing for guided selection and appropriate sequencing of targeted therapy agents. This activity also explores the importance of biomarker testing to guide treatment at therapy initiation and upon disease progression. Additionally, adaptive strategies are included for clinical, specialty, and managed care pharmacists to incorporate the latest advances in biomarker-driven NSCLC therapy into their practices.
This activity is designed to meet the educational needs of oncology pharmacists, pharmacy directors, and pharmacy residents.
At the conclusion of this enduring activity, participants will be able to:
- Review the most recent molecular testing guidelines for non–small-cell lung cancer (NSCLC), including clinically relevant biomarkers, recommended testing modalities, and implications for currently available and evolving treatments.
- Examine targeted therapies currently approved for NSCLC and appraise biomarker-driven approaches to selection and sequencing of therapy.
- Using a case-based approach, evaluate adaptive strategies pharmacists can employ to expand the uptake of guideline-recommended biomarker testing and ensure the appropriate selection of targeted therapy based on patient- and biomarker-specific factors.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This application-based activity is approved for 1.0 contact hours (0.10 CEUs) of continuing pharmacy education credit (JA0007101-0000-20-011-H01-P).
Creative Educational Concepts, Inc. certifies this activity for 1.0 hours of participation.
Planner and Faculty Disclosures
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.
Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.
Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Joan B. Fowler, PharmD, BCPS—has no relevant financial relationships to disclose in relation to the content of this activity.
Vanessa Carranza, PharmD—has no relevant financial relationships to disclose in relation to the content of this activity.
Josiah D. Land, PharmD, BCOP— has no relevant financial relationships to disclose in relation to the content of this activity.
Zofia Piotrowska, MD, MHS—has disclosed that she is a consultant for AstraZeneca, Genentech, Lilly Incyte, and Medtronic; and she receives grant/research support from AstraZeneca, Novartis, Spectrum, Takeda, and Tesaro.
Bryan C. Taylor, PharmD—has no relevant financial relationships to disclose in relation to the content of this activity.
Media: Internet Web Activity (PowerPoint slides and audio)
To receive a statement of credit, you must:
- Read the target audience, learning objectives, and author disclosures.
- Review the full content of the activity and reflect upon its teaching.
- Complete the questions and evaluation at the end of the activity.
- You must have a passing score of 75% on the post-test. You will have two (2) opportunities to complete the post-test.